| Submission | Feb. 07, 2025 |
| Submission [Line Items] | |
| Central Index Key | 0000818686 |
| Registrant Name | Teva Pharmaceutical Industries Limited |
| Form Type | S-3 |
| Submission Type | S-3ASR |
| Fee Exhibit Type | EX-FILING FEES |
| Offerings | Feb. 07, 2025 |
| Offering: 1 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Equity |
| Security Class Title | Ordinary Shares |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (4) Such ordinary shares may be represented by American Depositary Shares. Such American Depositary Shares are or will be registered on a separately filed registration statement on Form F-6. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 2 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Equity |
| Security Class Title | Units |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (5) This Registration Statement includes such currently indeterminate number of Units as may be issued at indeterminate prices. Units may consist of any combination of the securities being registered hereby or an indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 3 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Other |
| Security Class Title | Purchase Contracts |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (6) This Registration Statement includes such currently indeterminate number of Purchase Contracts as may be issued at indeterminate prices. Such Purchase Contracts may be issued together with any of the other securities being registered hereby. Purchase Contracts may require the holder thereof to purchase or sell any of the other securities registered hereby or to purchase or sell a basket of such securities, an index or indices of such securities or any combination of the above. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 4 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Senior Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 5 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Subordinated Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 6 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Other |
| Security Class Title | Guarantees of Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 7 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Senior Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 8 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Subordinated Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 9 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Senior Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 10 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Subordinated Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 11 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Senior Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 12 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Subordinated Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 13 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Senior Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 14 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Subordinated Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 15 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Senior Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 16 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Subordinated Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 17 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Senior Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Offering: 18 | |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Debt |
| Security Class Title | Subordinated Debt Securities |
| Offering Note | (1) Pursuant to General Instruction II.E of Form S-3, (2) This Registration Statement includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. Separate consideration may or may not be received for ordinary shares that are issuable upon the conversion of or exchange for any securities that provide for conversion or exchange into such ordinary shares. (3) In accordance with Rules 456(b) and 457(r) of the Securities Act of 1933, as amended, the Registrants are deferring payment of all of the registration fees and will pay such fees on a “pay as you go” basis. The Registrants will calculate the registration fee applicable to an offer of securities hereunder based on the fee payment rate in effect on the date of such fee payment. (7) Teva Pharmaceutical Industries Limited may fully and unconditionally guarantee the payment of principal and premium (if any) and interest on debt securities offered by Teva Pharmaceutical Finance IV, LLC, Te |
| Fees Summary | Feb. 07, 2025 USD ($) |
| Fees Summary [Line Items] | |
| Total Offering | $ 0 |
| Previously Paid Amount | 0 |
| Total Fee Amount | 0 |
| Total Offset Amount | 0 |
| Net Fee | $ 0 |
